Hypoparathyroidism Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market 1
Hypoparathyroidism Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Hypoparathyroidism Market:
DelveInsight’s ‘Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

DelveInsight’s ‘Hypoparathyroidism Market Insights, Epidemiology, and Market Forecast – 2032’ report delivers an in-depth understanding of the Hypoparathyroidism, historical and forecasted epidemiology as well as the Hypoparathyroidism market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

 

The Hypoparathyroidism market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Hypoparathyroidism market size from 2019 to 2032. The Report also covers current Hypoparathyroidism treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

 

Some of the key facts of the Hypoparathyroidism Market Report:

  • Among the five European countries, the UK had the highest prevalence of hypoparathyroidism, with  34,569, followed by Germany and France in 2021. On the other hand, Spain had the lowest prevalent population.
  • Among the major types of hypoparathyroidism, i.e., Chronic and transient hypoparathyroidism, the former accounts for a higher number of prevalent cases of hypoparathyroidism.

Key benefits of the report:

  • The Hypoparathyroidism market report covers a descriptive overview of Hypoparathyroidism, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
  • Comprehensive insight has been provided into Hypoparathyroidism epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for Hypoparathyroidism is provided, along with the assessment of new therapies which will impact the current treatment landscape.
  • A detailed review of the Hypoparathyroidism market, historical and forecasted, is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the 7MM Hypoparathyroidism market.

 

Got queries? Click here to learn more about Hypoparathyroidism Market Insights 

Hypoparathyroidism  Overview

Hypoparathyroidism is characterized by hypocalcemia and hyperphosphatemia due to a lack of parathyroid hormone (PTH) secretion or action. Hypoparathyroidism may occur as part of a pluriglandular autoimmune disorder or as a complex congenital defect, for example, in the autosomal dominant DiGeorge or hypoparathyroidism, deafness, and renal dysplasia (HDR) syndromes. Due to a deficiency of the parathyroid hormone, individuals may exhibit abnormally low levels of calcium in the blood (hypocalcemia) and high levels of phosphorus (hyperphosphatemia).

The most common cause of the disease is injury or removal of all 4 parathyroid glands. That can accidentally happen during surgery to remove the thyroid. Some people are born without these glands. And in some cases, the glands do not work well for unknown reasons.

Hypocalcaemia typically presents as perioral numbness, paresthesia, neurocognitive deficits, weakness, and carpopedal muscle spasms. Life-threatening complications, such as cardiac arrhythmias, laryngeal spasms, tetany, and seizures, can also occur.

Hypoparathyroidism Epidemiological Insights

 

  • HypoPTH happens when 1 or more of the parathyroid glands are not active enough. According to NORD, there are approximately 70,000 people with hypoPTH in the United States. It can affect individuals of any age. 
  • The total prevalent population of hypoparathyroidism in the 7MM was estimated to be 280,275 in 2021 and is expected to increase in 2032 at a CAGR of 1.22% during the study period [2019–2032]. 
  • Japan had 22,310 prevalent cases of hypoparathyroidism in 2021. 
  • According to analysis, it has been observed that Hypoparathyroidism prevalence varied across the 7MM countries based on the age-specific prevalence of the disease. For instance, the highest proportion was observed in the 65+ Years age group in the US, while in the EU-5 countries, people aged 55-64 Years accounted for the maximum patient pool. 

 

Hypoparathyroidism Epidemiological Segmentation 

  • Total  Hypoparathyroidism diagnosed Prevelant cases
  • Total  Hypoparathyroidism gender-specific Diagnosed Prevalent cases
  • Total Hypoparathyroidism type-specific Diagnosed Prevalent cases 
  • Total Hypoparathyroidism severity specific diagnosed prevalent cases
  • Total Hypoparathyroidism age-specific diagnosed specific cases

Hypoparathyroidism Market Outlook

The Hypoparathyroidism market outlook of the report helps to build a detailed comprehension of the historical, current and forecasted Hypoparathyroidism market trends by analyzing the impact of current Hypoparathyroidism therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of the Hypoparathyroidism market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Hypoparathyroidism market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Hypoparathyroidism market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @ Hypoparathyroidism Market Landscape

Hypoparathyroidism Key Companies

  • Ascendis Pharma
  • EnteraBio
  • Bridgebio
  • Calcilytix Therapeutics
  • And many more 

Hypoparathyroidism Therapies 

 

  • TransCon PTH  
  • EB612
  • Encaleret
  • And many more 

 

Hypoparathyroidism Market Drivers 

 

  • Rising prevalence of neck surgeries and autoimmune diseases
  • Rising awareness
  • Presence of major players

 

Hypoparathyroidism Market Barriers 

 

  • Knowledge gap
  • Poor quality of life
  • Availability of generics and off-label therapies

 

Table of Contents

  1. Key Insights 
  2. Report Introduction 
  3. Executive Summary of Hypoparathyroidism 
  4. Disease Background and Overview
  5. Epidemiology and patient population 
  6. Hypoparathyroidism   Emerging Therapies
  7. Hypoparathyroidism  Market Outlook
  8. Market Access and Reimbursement of Therapies
  9. Appendix
  10.  Hypoparathyroidism  Report Methodology
  11.  DelveInsight Capabilities
  12.  Disclaimer
  13. About DelveInsight

Click here to read more about Hypoparathyroidism Market Insights 

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432, Las Vegas NV
City: Las Vegas
State: United States
Country: United States
Website: https://www.delveinsight.com

Leave a Reply

Your email address will not be published. Required fields are marked *